Active implantable medical device (AIMD) that can attract and destroy residual tumor cells after lumpectomy
When possible, surgical resection of a primary tumor is still the standard treatment for most solid cancers. However, residual tumor cells may remain. These cells have a tendency to migrate to other organs or parts of the body, where they develop new tumors called metastases. In such cases, the cancer is referred to as metastatic. As a result, most cancer deaths are not caused by the primary tumor but rather by the formation of secondary tumors through the metastatic process.
The technology developed by the team consists of a microfluidic chip implanted in the resection area during lumpectomy. Its purpose is to prevent recurrence of the disease by capturing and destroying residual tumor cells.
This novel therapeutic approach is designed to prevent recurrence in patients with operable solid cancer. Breast cancer will be the first therapeutic application for developing the technology. Subsequently, the technology can be adapted to other solid cancers such as lung cancer, glioblastoma, etc.
MARKETED TECHNOLOGY | Microfluidics – Chemoattraction – Drug release